Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.
OBJECTIVE
To review current concepts regarding the pathogenesis of Graves ophthalmopathy (GO). We have presented this information in the context of potential target sites for novel disease therapies.


METHODS
Review of recent literature.


METHODS
Synthesis of recent literature.


RESULTS
Enlargement of the extraocular muscle bodies and expansion of the orbital fatty connective tissues is apparent in patients with GO. These changes result from abnormal hyaluronic acid accumulation and edema within these tissues and expanded volume of the orbital adipose tissues. Recent studies have suggested that the increase in orbital fat volume is caused by stimulation of adipogenesis within these tissues. The orbital fibroblast appears to be the major target cell of the autoimmune process in GO. A subset of these cells is capable of producing hyaluronic acid and differentiating into mature adipocytes, given appropriate stimulation. In addition, orbital fibroblasts from patients with GO have been shown to display immunoregulatory molecules and to express both thyrotropin receptors (TSHRs) and insulin-like growth factor 1 receptors (IGF-1Rs). Increased TSHR expression in the GO orbit appears to be the result of stimulated adipocyte differentiation. The activation of IGF-1R on orbital fibroblasts by immunoglobulins from GO patients results in increased production of both hyaluronic acid and molecules that stimulate the infiltration of activated T cells into areas of inflammation.


CONCLUSIONS
Potential targets for novel therapeutic agents to be used in GO include blocking T-cell costimulation, depleting B cells, inhibiting cytokine action, targeting the IGF-1R or the TSHR, and preventing connective tissue remodeling.
Garrity
James A
JA
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Bahn
Rebecca S
RS
D049970:Graves Ophthalmopathy / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D014057:Tomography, X-Ray Computed